Pre-treatment of loiasis caused by the parasitic African eye worm Loa loa in Gabon with the antiparasitic medication albendazole among patients with a high risk of adverse events after another antiparasitic administration, ivermectin

Submission date 22/11/2022	Recruitment status No longer recruiting	Prospectively registered		
		☐ Protocol		
Registration date 29/11/2022	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited 19/08/2024	Condition category Infections and Infestations	Individual participant data		

Plain English summary of protocol

Background and study aims

In areas where onchocerciasis (river blindness) and loiasis (caused by the parasitic African eye worm Loa loa, so called because it localizes to the conjunctiva of the eye) are co-endemic, the Community-Directed Treatment with Ivermectin (CDTI) strategy for onchocerciasis control is hampered by the presence of hypermicrofilaremic individuals who have Loa loa microfilaraemia exceeding 8,000 microfilariae per milliliter of blood (mf/ml). They are at risk of developing posttreatment severe and/or serious adverse reactions (SARs) after ivermectin (IVM) administration. These SARs are frequent in almost 10.0% of the exposed population of loiasis hyperendemic settings such as in Gabon where both filariasis is endemic, and where Loa infection prevalence exceeds 40.0% in some villages with Onchocerca volvulus-infected individuals. A treatment that can safely reduce high Loa loa microfilaremia (HLMF) below the risk threshold for SARs for a time sufficiently long enough to implement IVM mass drug administration, would be a major contribution to efforts to control and eliminate onchocerciasis. Antifilarial albendazole is considered an alternative to diethylcarbamazine and IVM for the treatment of loiasis that can reduce hypermicrofilaraemia by at least 50% or even below 8,000 mf/ml for at least 4 months. Moreover, this drug is equally effective on soil-transmitted helminthiases (STH) which are also prevalent in loiasis-onchocerciasis co-endemic settings. We hypothesize that a 30-day treatment of HLMF patients with albendazole will be sufficient to reduce the microfilaraemia below the threshold of 8,000 mf/ml and will allow this neglected population to be eligible for the CDTI for onchocerciasis control in co-endemic areas. The objective of this study is to assess and compare the safety and effects of two daily doses of albendazole for 30 days for the treatment of hypermicrofilaremic loiasis in Bitam and Minvoul villages in Gabon with Loa loa-Onchocerca volvulus and STH co-endemicity.

Who can participate?

Adults aged between 18 and 75 years old in Bitam and Minvoul villages in Gabon

What does the study involve?

After biological examinations, positive patients with Loa loa microfilaremia will be approached and asked if they consent to participate in the study and stay within the study area for 2 years. A total of 105 hypermicrofilaraemic individuals will be randomly put in one of the treatment arms. The comparator arm will be composed of 35 low microfilaraemic patients (> 8,000 mf/ml) treated with 400mg albendazole. The experimental arms will comprise people with > 8,000 mf/ml treated with 400 and 800 mg albendazole. The Adequate Clinical and Parasitological Response (ACPR) defined as the reduction of microfilaraemia below 8,000mf/ml will be determined for all groups at day 30. For the first time albendazole pharmacokinetic and metabolites will be determined in filarial-infected individuals using high-performance liquid chromatography and analysed according to the microfilaraemia. The follow-up will last 180 days and the parasite clearance as well as impact on STH prevalence will be evaluated. This will be the first study in Gabon evaluating a pretreatment test and treatment strategy for onchocerciasis control including loiasis and STH.

What are the possible benefits and risks of participating?

Patients will be managed for microfilaremic loiasis first. According to the National Ethical Committee for Research in Gabon, blood count, malaria, intestinal and urine diagnosis will be also performed. Closed management of known adverse events of the albendazole treatment with the administration of antiH2 molecule will be carried out mainly for pruritus. Blood collection may cause local inflammation and pain. Also, participants will be inconvenienced by being expected to attend daily appointments for one month due to the medical appointment each day with the study team.

Where is the study run from? Université des Sciences de la Santé (Gabon)

When is the study starting and how long is it expected to run for? June 2019 to February 2023

Who is funding the study? European and Developing Countries Clinical Trial Partnership (EDCTP) (Netherlands)

Who is the main contact?
Prof Marielle Karine Bouyou-Akotet, mariellebouyou@gmail.com (Gabon)
Dr Noé Patrick M'Bondoukwé, mbondoukwenoe@gmail.com (Gabon)

Contact information

Type(s)

Scientific

Contact name

Prof Marielle Karine Bouyou-Akotet

ORCID ID

https://orcid.org/0000-0002-7992-4630

Contact details

Department of Parasitology-Mycology-tropical Medicine Faculté de Medecine

Université des Sciences de la Santé Libreville Gabon 4009 +24166303105 mariellebouyou@gmail.com

Type(s)

Principal investigator

Contact name

Dr Noé Patrick M'Bondoukwé

ORCID ID

https://orcid.org/0000-0002-4994-3355

Contact details

Department of Parasitology-Mycology-tropical Medicine
Faculté de Medecine
Université des Sciences de la Santé
Libreville
Gabon
4009
+24174122125
mbondoukwenoe@gmail.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Protocol number: 0053/2022/CNER/P/SG

Study information

Scientific Title

Pre-treatment of hypermicrofilaremic loiasis for eligibility to the community-directed ivermectin intervention for onchocerciasis control in co-endemic settings of Gabon

Acronym

PHYLECOG

Study objectives

Albendazole has been safely used for the reduction of Loa loa microfilaraemia but there is no formal recommendation for this purpose or for loiasis treatment. We hypothesize that a 30-day treatment in patients with hypermicrofilaraemic loiasis will be sufficient to reduce the

microfilaraemia below the threshold of 8,000 microfilariae (mf)/ml and allow this neglected population to be eligible for the community-directed ivermectin (CDTI) intervention for onchocerciasis control in co-endemic areas. Moreover, a trial investigating albendazole pharmacokinetic (PK) data and its relationship with microfilaraemia will demonstrate its curative effect.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 15/11/2021, Ethical National Committee for the Research (B.P. 2117 - Libreville, Gabon; +241 77 56 41 95 - HB; gaboncner49@gmail.com), ref: none provided

Study design

Interventional single-blind non-randomized phase IIb trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Hypermicrofilaremic loiasis

Interventions

A 30-day treatment of albendazole will be given in three experimental groups: a control group (< 8000 microfilariae (mf)/ml) who will receive 400 mg albendazole, and two experimental groups (> 8000 mf/ml) who will receive 400 and 800 mg albendazole. A histamine Type-2 receptor antagonist (H2 blocker; 10 mg/kg) will also be given for 7 first days of the treatment. Blood samples for parasitological diagnosis (direct examination and leukoconcentration) will be performed on Day (D0) before the initiation of the treatment, at D2, 7,14 and 28. Socioeconomic and demographic data, clinical signs and adverse events will be recorded on a standardized Case Report Form.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Albendazole

Primary outcome(s)

Day 30 Adequate Clinical and Parasitological Response (ACPR) measured using parasitological diagnosis (direct examination and leukoconcentration techniques) for blood count of microfilariae, clinical diagnosis for the disappearance of loiasis symptoms and pharmacokinetic (PK) measurements with high-performance liquid chromatography (HPLC) on day 30

The ACPR corresponds to the reduction of microfilaraemia below the threshold of 8,000 mf/m without parasite recrudescence (recurrence).

Key secondary outcome(s))

Variables measured using parasitological diagnosis by direct examination and leukoconcentration techniques on blood samples:

- 1. Day 30 crude ACPR measured using microscopy on day 30
- 2. Day 60 crude ACPR measured using microscopy on day 60
- 3. Day 90 crude ACPR measured using microscopy on day 90
- 4. Day 180 total microfilaraemia clearance on day 180
- 5. Microfilaraemia at baseline then at 48 h, and on days 7, 14, 30, 60, 90, and 180
- 6. Time to microfilaraemia clearance per individual
- 7. Time to microfilaraemia reduction until 8,000 mf/ml
- 8. Time to recrudescence or re-infection, per individual
- 9. Observed microfilaraemia reduction rate (MRR) on days 7, 14, 30, 90, and 180
- 10. Observed frequency of soil-transmitted helminthiases (STH) at baseline and on day 90 after inclusion

Completion date

28/02/2023

Eligibility

Key inclusion criteria

- 1. Age between 18 and 75 years with a weight below 90.1 kg
- 2. Positive for hypermicrofilaremic loiasis (> 8000 mf/ml for the treatment arm and under 8,000 mf/ml for the comparative arm) by blood microscopic direct examination
- 3. Signed written informed consent
- 4. Agree to comply with study procedures, including the provision of a blood sample and two stool samples at the beginning (baseline) and approximately six months after treatment
- 5. Willingness to stay in the village over the following 2 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Sex

Αll

Key exclusion criteria

- 1. Presence of acute or uncontrolled systemic illnesses (e.g. severe anemia, infection, clinical malaria) as assessed by a medical doctor, upon initial clinical assessment and liver function tests
- 2. Known or reported history of chronic illness such as HIV, acute or chronic hepatitis, cancer, diabetes, chronic heart disease or renal disease

- 3. Prior treatment with anthelmintics (eg, diethylcarbamazine [DEC], suramin, ivermectin, mebendazole or albendazole) within 4 weeks before the screening
- 4. Known or suspected allergy to benzimidazoles
- 5. Pregnant (urine testing) or breastfeeding women

Date of first enrolment

13/11/2022

Date of final enrolment

28/02/2023

Locations

Countries of recruitment

Gabon

Study participating centre Université des Sciences de la Santé

Department of Parasitology-Mycology-Tropical Medicine Faculty of Medicine Libreville Gabon 4009

Sponsor information

Organisation

Université des Sciences de la Santé

ROR

https://ror.org/00yk3tm64

Funder(s)

Funder type

Research organisation

Funder Name

European and Developing Countries Clinical Trials Partnership

Alternative Name(s)

Le partenariat Europe-Pays en développement pour les essais cliniques, A Parceria entre a Europa e os Países em Desenvolvimento para a Realização de Ensaios Clínicos, The European & Developing Countries Clinical Trials Partnership, European and Developing Countries Clinical Trials, EDCTP

Funding Body Type

Private sector organisation

Funding Body Subtype

International organizations

Location

Netherlands

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study will be published as a supplement to the results publication.

IPD sharing plan summary

Published as a supplement to the results publication

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Preprint results		17/08/2024	19/08/2024	No	No